AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28690076 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended care including reassurance, simple analgesia, and advice to stay active and avoid bed rest.
Number of subjects: 1643
Study 26104013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 33
Study 26104013 — intervention group
Group type: COMPARATOR
Intervention: Typical American childhood diet (TACD)
Number of subjects: 33
Study 26104013 — intervention group
Group type: COMPARATOR
Intervention: TACD
Number of subjects: 33
Study 23350053 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine maleate
Number of subjects: 345
Study 23350053 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated group
Number of subjects: 345
Study 21262880 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Birth Weight (VLBW)
Number of subjects: 160
Study 21262880 — intervention group
Group type: COMPARATOR
Intervention: Term Birth
Number of subjects: 160
Study 21262880 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during the first 2 postnatal weeks
Number of subjects: 160
Study 18922426 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan, 0.1 microg/kg/min, started after the induction of anesthesia (Group B)
Number of subjects: 60
Study 18922426 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan, 0.1 microg/kg/min, started immediately after the release of the aortic cross‐clamp (Group C)
Number of subjects: 60
Study 18922426 — intervention group
Group type: COMPARATOR
Intervention: Milrinone, 0.5 microg/kg/min, started after the release of the aortic cross‐clamp (Group A)
Number of subjects: 60
Study 16539559 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT with BisCover varnished enamel
Number of subjects: 100
Study 16539559 — intervention group
Group type: EXPERIMENTAL
Intervention: Unite with BisCover varnished enamel
Number of subjects: 100
Study 16539559 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT without BisCover (dry enamel)
Number of subjects: 100
Study 16539559 — intervention group
Group type: EXPERIMENTAL
Intervention: Unite without BisCover (dry enamel)
Number of subjects: 100
Study 16539559 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT with no additional primer on BisCover
Number of subjects: 100
Study 12820857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (10 mg)
Number of subjects: 100
Study 12820857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11208406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 40 mg
Number of subjects: 38
Study 11208406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg
Number of subjects: 38
Study 11208406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg
Number of subjects: 38
Study 11208406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 40 mg in 3x phase
Number of subjects: 38
Study 11208406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg in 2x phase
Number of subjects: 38
Study 11208406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg in once-daily phase
Number of subjects: 38
Study 11208406 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg in once-daily phase
Number of subjects: 38
Study 11208406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8879340 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (cilazapril)
Number of subjects: 257
Study 8879340 — intervention group
Group type: COMPARATOR
Intervention: Beta‐adrenoceptor blocker (atenolol)
Number of subjects: 257
Study 1642341 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum thiopental concentration of 10-30 micrograms/ml for 5 min
Number of subjects: 26
Study 1642341 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum thiopental concentration of 40-90 micrograms/ml
Number of subjects: 26
Study 6380114 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbazol A (with antacid component)
Number of subjects: 64
Study 6380114 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbacid B (without antacid component)
Number of subjects: 64
Study 6380114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29351646 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum training program (weekly supervised exercise class focusing on pelvic floor muscle strength training and daily home training)
Number of subjects: 175
Study 29351646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study 29351646 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum training program
Number of subjects: 175
Study 29351646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study 29693865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil monotherapy
Number of subjects: 30
Study 23348043 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EX) - core strengthening home exercise program thrice weekly for 6 weeks
Number of subjects: 24
Study 23348043 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 24
Study 23706759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg once or twice daily)
Number of subjects: 278
Study 23706759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 23706759 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 278
Study 23706759 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin and Placebo
Number of subjects: 278
Study 20502283 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg orally twice daily for 5 days at the onset of bleeding)
Number of subjects: 66
Study 20502283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taken for 5 days at the onset of bleeding)
Number of subjects: 66
Study 20502283 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 66
Study 20502283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 20502283 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline and Placebo
Number of subjects: 66
Study 18556141 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with absorbed dose >1.0 Gy to the contralateral breast (CB)
Number of subjects: 2107
Study 18556141 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with absorbed dose to the contralateral breast (CB)
Number of subjects: 2107
Study 16670154 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CHO solution
Number of subjects: 9
Study 16670154 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 9
Study 12792873 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole-promastigote vaccine cocktail plus BCG adjuvant
Number of subjects: 48
Study 12792873 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 48
Study 10722770 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated analysis of digitally recorded oximetry
Number of subjects: 246
Study 10722770 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 246
Study 10722770 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG) with EEG based arousals
Number of subjects: 246
Study 9187908 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP), 30 micrograms/day intranasally for 6 weeks
Number of subjects: 114
Study 9187908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin alone
Number of subjects: 114
Study 9187908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin plus Desmopressin (DDAVP)
Number of subjects: 114
Study 8457502 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of oral acetazolamide (group A)
Number of subjects: 54
Study 8457502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 54
Study 3515419 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography (DSA) alone
Number of subjects: 0
Study 3515419 — intervention group
Group type: COMPARATOR
Intervention: Conventional film‐based angiography alone
Number of subjects: 0
Study 3515419 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined study (DSA and conventional angiography)
Number of subjects: 0
Study 30075329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise five days/week (supervised three days/week), 45 min/session, achieving 70-80% heart rate reserve
Number of subjects: 212
Study 30075329 — intervention group
Group type: COMPARATOR
Intervention: Usual inactivity (Control)
Number of subjects: 212
Study 26884081 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hs-cTnT levels
Number of subjects: 5407
Study 24588813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pharmacist-managed intervention for 6 months
Number of subjects: 37
Study 23784069 — intervention group
Group type: EXPERIMENTAL
Intervention: lpa bean high in PPs
Number of subjects: 20
Study 23784069 — intervention group
Group type: EXPERIMENTAL
Intervention: lpa bean low in PPs
Number of subjects: 20
Study 23784069 — intervention group
Group type: COMPARATOR
Intervention: parent high in PPs
Number of subjects: 20
Study 23784069 — intervention group
Group type: COMPARATOR
Intervention: parent low in PPs
Number of subjects: 20
Study 21058884 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (stimulator tapping and regular massage twice a day for 4 weeks)
Number of subjects: 33
Study 21058884 — intervention group
Group type: COMPARATOR
Intervention: Sham auricular acupressure (tapping at sham points without massage stimulation)
Number of subjects: 33
Study 18262041 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation during pregnancy
Number of subjects: 917
Study 18262041 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (Control)
Number of subjects: 917
Study 16606763 — intervention group
Group type: EXPERIMENTAL
Intervention: Trientine hydrochloride 500 mg 2 times per day plus 50 mg of zinc 2 times per day
Number of subjects: 48
Study 16606763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate 20 mg 3 times per day with meals and 20 mg 3 times per day between meals plus 50 mg of zinc 2 times per day
Number of subjects: 48
Study 12742878 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent priming with alcohol self‐assessment and education just before health checkups (group 2)
Number of subjects: 444
Study 12742878 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent priming and provider prompting with the adolescent's self‐assessment and a patient education brochure (group 3)
Number of subjects: 444
Study 12742878 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group 1)
Number of subjects: 444
Study 10946883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (200 mg/day for 2 weeks every 3 months)
Number of subjects: 57
Study 10946883 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 57
Study 8610730 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention
Number of subjects: 208
Study 8610730 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study 1428733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (2 mg/M2/dose) plus Prednisone (60 mg/M2/dose)
Number of subjects: 76
Study 1428733 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (2 mg/M2/dose) plus Prednisone (60 mg/M2/day)
Number of subjects: 76
Study 3897404 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg/day for three consecutive days for three months
Number of subjects: 0
Study 3897404 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29219855 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second surveys of hinge abduction assessment
Number of subjects: 30
Study 29219855 — intervention group
Group type: EXPERIMENTAL
Intervention: Third and fourth surveys of hinge abduction assessment
Number of subjects: 30
Study 29219855 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second readings of intraobserver agreement
Number of subjects: 30
Study 29219855 — intervention group
Group type: EXPERIMENTAL
Intervention: Third and fourth readings of intraobserver agreement
Number of subjects: 30
Study 29219855 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus sessions for diagnostic features
Number of subjects: 30
Study 29362928 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:200,000 adrenaline
Number of subjects: 50
Study 29362928 — intervention group
Group type: COMPARATOR
Intervention: amalgamated mixture of 2% lignocaine and 0.5% bupivacaine
Number of subjects: 50
Study 27430123 — intervention group
Group type: EXPERIMENTAL
Intervention: APL-130277 10 mg
Number of subjects: 19
Study 27430123 — intervention group
Group type: EXPERIMENTAL
Intervention: APL-130277 (dosing up to 30 mg if needed)
Number of subjects: 19
Study 25255346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal septal splints
Number of subjects: 60
Study 25255346 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 60
Study 23165660 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, training, and technical support to promote use of a standard bed alarm system
Number of subjects: 27672
Study 23165660 — intervention group
Group type: COMPARATOR
Intervention: Bed alarms available but not formally promoted or supported
Number of subjects: 27672
Study 20097537 — intervention group
Group type: EXPERIMENTAL
Intervention: Low DHA intake (lowest tertile)
Number of subjects: 55
Study 20097537 — intervention group
Group type: COMPARATOR
Intervention: Highest tertile of DHA consumption
Number of subjects: 55
Study 18620950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine and amodiaquine
Number of subjects: 6758
Study 18620950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6758
Study 18620950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT)
Number of subjects: 6758
Study 19333052 — intervention group
Group type: EXPERIMENTAL
Intervention: Unroofing and marsupialization (UM)
Number of subjects: 140
Study 19333052 — intervention group
Group type: COMPARATOR
Intervention: Rhomboid excision and Limberg flap (RELP)
Number of subjects: 140
Study 12845425 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) graft fixed with titanium screws
Number of subjects: 7
Study 12845425 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus-bone composite (SBC) allograft fixed with bioabsorbable screws
Number of subjects: 7
Study 11556655 — intervention group
Group type: COMPARATOR
Intervention: heparin 5,000 units s.c.
Number of subjects: 30
Study 11556655 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin 4,500 anti‐Xa IU without preservative s.c.
Number of subjects: 30
Study 11556655 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin 4,500 anti‐Xa IU without preservative i.v.
Number of subjects: 30
Study 11556655 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin 12,250 anti‐Xa IU with preservative s.c.
Number of subjects: 30
Study 11556655 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin 4,500 anti‐Xa IU with preservative s.c.
Number of subjects: 30
Study 9597562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (40 mg)
Number of subjects: 9
Study 9597562 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 9
Study 9597562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8165070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal dexamethasone (DEX) treatment (6 mg four times at 12-hour intervals)
Number of subjects: 157
Study 8165070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal dexamethasone (DEX) treatment combined with exogenous human surfactant therapy
Number of subjects: 157
Study 3210111 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 43
Study 3210111 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43
Study 30802718 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) using a portable device for 8 weeks (23 min/5 days/week)
Number of subjects: 19
Study 30802718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS intervention)
Number of subjects: 19
Study 28204733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tetracaine
Number of subjects: 42
Study 28204733 — intervention group
Group type: COMPARATOR
Intervention: 20% benzocaine
Number of subjects: 42
Study 26580235 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 26
Study 24867846 — intervention group
Group type: COMPARATOR
Intervention: Frovatriptan 2.5 mg (Frova)
Number of subjects: 314
Study 24867846 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 25 mg (FroDex25)
Number of subjects: 314
Study 24867846 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 37.5 mg (FroDex37.5)
Number of subjects: 314
Study 22872107 — intervention group
Group type: EXPERIMENTAL
Intervention: Asha-Life intervention
Number of subjects: 68
Study 22872107 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 68
Study 19244152 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium supplementation (14 g/day for 3 months)
Number of subjects: 86
Study 19244152 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 86
Study 17492348 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of amino acids parenterally (Group 1)
Number of subjects: 14
Study 17492348 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g of amino acids parenterally (Group 2)
Number of subjects: 14
Study 15618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DEF) 4 g i.v. infusion for 8 hours starting immediately after the induction of anaesthesia (group D)
Number of subjects: 45
Study 15618054 — intervention group
Group type: COMPARATOR
Intervention: Dextrose solution as placebo for 8 hours (group C)
Number of subjects: 45
Study 15618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DEF) infusion in patients with lower EF (below 38%)
Number of subjects: 45
Study 15618054 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DEF) infusion in patients with higher EF (above 38%)
Number of subjects: 45
Study 12122920 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonists
Number of subjects: 0
Study 10457621 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer-preparation letter and verbal explanation
Number of subjects: 50
Study 10457621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transfer-preparation letter)
Number of subjects: 50
Study 8543357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin at a concentration of 10 mg/l
Number of subjects: 0
Study 8543357 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontamination of the liquid culture before subculture on solid medium
Number of subjects: 0
Study 2111629 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow setting A (VFG of 75 ml.min‐1.kg‐1 and VE of 150 ml.min‐1.kg‐1)
Number of subjects: 59
Study 2111629 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow setting B (VFG of 110 ml.min‐1.kg‐1 and VE of 175 ml.min‐1.kg‐1)
Number of subjects: 59
Study 85583 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc administration (0.02 mg Zn per kg of body weight in the form of zinc sulphate)
Number of subjects: 27
Study 85583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31043691 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MiP)
Number of subjects: 326
Study 31043691 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR2 concentrations in the highest quartile within 6 weeks of delivery
Number of subjects: 326
Study 31043691 — intervention group
Group type: COMPARATOR
Intervention: Daily TMP/SXT
Number of subjects: 326
Study 28463010 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 65
Study 28463010 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 65
Study 25592287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics rounds led by a philosopher/ethicist
Number of subjects: 2
Study 25592287 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 2
Study 24015717 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solutions containing soy‐soluble polysaccharides (6%)
Number of subjects: 12
Study 24015717 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solutions containing flaxseed gum (0.7%)
Number of subjects: 12
Study 24015717 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solutions containing guar gum (0.23%)
Number of subjects: 12
Study 24015717 — intervention group
Group type: COMPARATOR
Intervention: Dairy‐based beverages with 0% or 1% soluble fiber added
Number of subjects: 12
Study 24015717 — intervention group
Group type: COMPARATOR
Intervention: Dairy‐based puddings with 0% or 1% soluble fiber added
Number of subjects: 12
Study 24015717 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy‐soluble polysaccharide‐fortified dairy products
Number of subjects: 12
Study 24015717 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed gum‐fortified dairy products
Number of subjects: 12
Study 24015717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber‐fortified fluid and gelled dairy‐based study treatments
Number of subjects: 12
Study 21357374 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise
Number of subjects: 60
Study 21357374 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min exercise
Number of subjects: 60
Study 19603365 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional training including WBV (VTG)
Number of subjects: 151
Study 19603365 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training (TG)
Number of subjects: 151
Study 19603365 — intervention group
Group type: COMPARATOR
Intervention: Wellness-control group (CG)
Number of subjects: 151